JamesM.FordMD

Oncology • Stanford, CA

Cancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer, Hematologic Oncology

Professor of Medicine/Oncology and Genetics

Join to view full profile

Dr. Ford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Ford's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000
Is this information wrong?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 1991 - 1994
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1990 - 1991
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1989 - 1990
Yale School of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1990 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer Start of enrollment: 2001 Nov 01
Completed
Molecular Genetic and Pathological Studies of Anal Tumors Start of enrollment: 2004 Sep 01
Terminated
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Start of enrollment: 2002 Jan 01
Recruiting
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Start of enrollment: 2009 Feb 01
Completed
Phase 2
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples Start of enrollment: 2001 Aug 01
Recruiting
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma Start of enrollment: 2002 Aug 01
Recruiting
Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Start of enrollment: 2001 Jul 01
Terminated
The Gastric Cancer Foundation: A Gastric Cancer Registry Start of enrollment: 2011 Apr 01
Recruiting
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples Start of enrollment: 2005 Sep 01
Completed
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors Start of enrollment: 2014 Jul 28
Recruiting
Join now to see all

Publications & Presentations

PubMed

Repurposing mebendazole against triple-negative breast cancer CNS metastasis.
Sophia B Chernikova, Yuelong Wang, Thy T H Trinh, David E Solow-Cordero, Ludmila Alexandrova, Kerriann M Casey, Elizabeth Alli, Abhishek Aggarwal, Tyler Quill, Brian J...> ;Journal of Neuro-Oncology. 2024 Apr 2
Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease.
Adrian Rodrigues, Sophia B Chernikova, Yuelong Wang, Thy T H Trinh, David E Solow-Cordero, Ludmila Alexandrova, Kerriann M Casey, Elizabeth Alli, Abhishek Aggarwal, Ty...> ;Research Square. 2024 Feb 5
1 citations
The New NCI Precision Medicine Trials.
Lyndsay N Harris, Charles D Blanke, Harry P Erba, James M Ford, Robert J Gray, Michael L LeBlanc, Siwen Hu-Lieskovan, Mark R Litzow, Selina M Luger, Funda Meric-Bernst...> ;Clinical Cancer Research. 2023 Dec 1
10 citations
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Shere...> ;Nature Communications. 2023 Feb 6
Therapeutic Implications of Oncogenic Missense() Mutations in Gastric Adenocarcinoma.
Daniel A King, Julianna J Weiel, Rochelle Reyes, Meredith Mills, Antonita Itchon, George A Fisher, James M Ford, Carlos J Suarez> ;JCO Precision Oncology. 2023 Feb 1
11 citations
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, Geoffrey I Shapiro, Lisa M McShane, Boris Freidlin, Roisin E O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gar...> ;Clinical Cancer Research. 2023 Apr 14
1 citations
Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.
Hannah Llorin, Madeline Graf, Nicolette Chun, James Ford> ;Cancer Genetics. 2022 Nov 1
104 citations
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
C E Geyer Jr, J E Garber, R D Gelber, G Yothers, M Taboada, L Ross, P Rastogi, K Cui, A Arahmani, G Aktan, A C Armstrong, M Arnedos, J Balmaña, J Bergh, J Bliss, S Del...> ;Annals of Oncology. 2022 Dec 1
38 citations
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Joshua J Gruber, Anosheh Afghahi, Kirsten Timms, Alyssa DeWees, Wyatt Gross, Vasily N Aushev, Hsin-Ta Wu, Mustafa Balcioglu, Himanshu Sethi, Danika Scott, Jessica Fora...> ;Nature Cancer. 2022 Oct 1
12 citations
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
June Y Hou, Jocelyn S Chapman, Ekaterina Kalashnikova, William Pierson, Karen Smith-McCune, Geovanni Pineda, Reena Marie Vattakalam, Alexandra Ross, Meredith Mills, Ca...> ;Gynecologic Oncology. 2022 Nov 1
The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer.
Alison F Almeda, Susan M Grimes, HoJoon Lee, Stephanie Greer, GiWon Shin, Madeline McNamara, Anna C Hooker, Maya M Arce, Matthew Kubit, Marie C Schauer, Paul Van Humme...> ;Cancer Epidemiology, Biomarkers & Prevention. 2022 Sep 2
1 citations
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, Quynh Thu Le, Sue S Yom, Thomas J Gallow...> ;Journal of the National Cancer Institute. 2022 Dec 8
3 citations
Somatic tumor testing implications for Lynch syndrome germline genetic testing.
Kathleen Barrus, Natasha Purington, Nicolette Chun, Uri Ladabaum, James M Ford> ;Cancer Genetics. 2022 Jun 1
6 citations
Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
Stephanie Archer, Nichola Fennell, Ellen Colvin, Rozelle Laquindanum, Meredith Mills, Romy Dennis, Francisca Stutzin Donoso, Rochelle Gold, Alice Fan, Kate Downes, Jam...> ;Cancers. 2022 May 31
1 citations
A Novel Framework for the Next Generation of Precision Oncology Targets.
Christopher T Chen, James M Ford> ;JAMA Oncology. 2022 Jul 1
9 citations
Phase II Study of Taselisib in-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, Josh D Lauring, Edith P Mitchell, James A Zwiebel, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinste...> ;JCO Precision Oncology. 2022 Feb 1
4 citations
Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes.
Joseph D Forrester, Deshka Foster, James M Ford, Teri A Longacre, Uri Ladabaum, Sara Fry, Jeffrey A Norton> ;Cancers. 2022 Jan 30
Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations.
Uri Ladabaum, James M. Ford, George A. Poultsides, Jeffrey A. Norton> ;Gastrointestinal Endoscopy. 2021 Aug 17
11 citations
Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
Rachel Hodan, Kerry Kingham, Kristina Cotter, Ann K. Folkins, Allison W. Kurian, James M. Ford, Teri A. Longacre> ;Cancer Medicine. 2021 Feb 1
One Step Further Toward Defining the Exceptional Cancer Responder.
James M. Ford, Beverly S. Mitchell> ;Journal of the National Cancer Institute. 2021 Jan 4
4 citations
A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma.
Lu Chen, Rebecca R. Bellone, Yan Wang, M. Singer-Berk, Kaoru Sugasawa, James M. Ford, Steven E. Artandi> ;DNA Repair. 2021 Jan 1
18 citations
Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
Julie O. Culver, Charité Ricker, Joseph D Bonner, John Kidd, Duveen Sturgeon, Rachel Hodan, Kerry Kingham, Katrina Lowstuter, Nicolette M. Chun, Alexandra Lebensohn, C...> ;Cancer. 2021 Apr 15
2 citations
Clinical outcome event adjudication in a 10-year prospective study of nucleos(T)ide analogue therapy for chronic hepatitis b
Joseph K. Lim, Alex Y. Chang, Atif Zaman, Paul J. Martin, Conrado M Fernandez-Rodriguez, Mete Korkmaz, Simona Rossi, James M. Ford, Tamara Noonan, E. Cooney, Victor J....> ;Journal of Clinical and Translational Hepatology. 2020 Oct 10
9 citations
Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.
Kara N. Maxwell, Brandon Wenz, Abha Kulkarni, Bradley Wubbenhorst, Kurt D'Andrea, Benita Weathers, Noah Goodman, Joseph Vijai, Jenna Lilyquist, Steven N. Hart, Thomas ...> ;JCO Precision Oncology. 2020 Aug 19
174 citations
Hereditary Diffuse Gastric Cancer: Updated Clinical Practice Guidelines
Vanessa Blair, Maybelle McLeod, Fátima Carneiro, Daniel G. Coit, Johanna L. D'Addario, Jolanda M. van Dieren, Kirsty L. Harris, Nicoline Hoogerbrugge, Carla Oliveira, ...> ;The Lancet. Oncology. 2020 Aug 1
Join now to see all

Press Mentions

The Bay Area's Top Doctors of 2019January 17th, 2019
Why Become a Doctor? Research plus Caregiving Equals “An Incredibly Exciting Career”January 3rd, 2017
Seven Research Teams Receive Intermountain-Stanford Grant AwardOctober 31st, 2016
Join now to see all